Abstract
How Do Commercial Insurance Plans Fare Under Proposed Prescription Drug Price Regulation?
Highlights
The 2 leading current proposals to control prescription drug pricing in the US, H.R. 3 and H.R. 5260, propose new negotiation authority for the Secretary of Health and Human Services to establish prices for selected high-expenditure drugs
While the prospect of federal price negotiation of drugs for all US payers has been discussed for decades,[2] the current debate in the US Congress has raised the possibility of a policy design that would be limited to Medicare only
Such a policy design has led to concerns regarding direct harm, namely that passage of a Medicare-only policy will cause pharmaceutical companies to increase the prices of drugs paid by commercial insurers and their beneficiaries
Summary
The 2 leading current proposals to control prescription drug pricing in the US, H.R. 3 and H.R. 5260, propose new negotiation authority for the Secretary of Health and Human Services to establish prices for selected high-expenditure drugs. While the prospect of federal price negotiation of drugs for all US payers has been discussed for decades,[2] the current debate in the US Congress has raised the possibility of a policy design that would be limited to Medicare only.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
